Adicet Bio, Inc., a pioneering biotechnology firm, is dedicated to the discovery and development of "off-the-shelf" gamma delta T cell therapies aimed at combating cancer and other illnesses. Their innovative approach involves genetically modifying gamma delta T cells by integrating both chimeric antigen receptors (CARs) and T-cell receptor-mimicking antibodies. This proprietary engineering is designed to achieve highly selective tumor targeting, bolster both innate and adaptive anti-tumor immune responses, and enhance cell persistence for durable therapeutic outcomes in patients.